Legislation Reproductive Rights Roe v. Wade Abortion Bans State Laws Supreme Court Abortion Rights Abortion Laws Pro-Life Movement Public Opinion Republican Party Abortion Ban Abortion Access Abortion Restrictions Federal Abortion Ban State Legislation State Bans Anti-Abortion Movement Access Texas Abortion Legislation Anti-Abortion Groups National Ban Republican Candidates Mifepristone Federal Ban Women's Rights Democratic Party National Abortion Ban Laws Florida State Abortion Laws Texas Supreme Court State Abortion Bans Pro-life Pro-life Movement Bans Medication Abortion Legal Issues Late-term Abortion Abortion Pill Ballot Measures Legalization Six-Week Abortion Ban Trump's stance on abortion Anti-Abortion Laws Arizona Constitutional Amendments Lawsuit Republican Stance Elections Abortion Policies March for Life Federal Law Trump's Position Donald Trump State Restrictions Abortion Policy Exceptions FDA Legal Challenges Late-Term Abortion FDA Approval Reproductive Health Care Roe v Wade Supreme Court Ruling Pro-Choice Movement Democrats Pro-Life Ohio Fetal Personhood State Constitutional Amendments Pro-Life Advocacy Abortion Debate Republicans Texas Abortion Ban Political Parties Anti-Abortion Activism Criminalization Anti-Abortion Legislation Supreme Court Rulings State vs Federal Regulation Late-term abortion Debate Trump State Policies Ron DeSantis Anti-Abortion Candidates Trump's Stance Pro-Choice Republican Views Federal Legislation State Referendums Lawsuits Idaho State Abortion Restrictions State-Level Bans Missouri Kentucky Abortion-rights Activists
Speakers at a Capitol press conference said the FDA’s promised mifepristone safety review has stalled.
